Epidemiology and management of hyperlipidemia.
Karr S.
Am J Manag Care. 2017 Jun;23(9 Suppl):S139-S148.
Lipid metabolism and hyperlipidemia in dogs.
Xenoulis PG, Steiner JM.
Vet J. 2010 Jan;183(1):12-21. doi: 10.1016/j.tvjl.2008.10.011. Epub 2009 Jan 23.
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.
Yanai H, Adachi H, Hakoshima M, Katsuyama H.
Int J Mol Sci. 2023 Sep 11;24(18):13942. doi: 10.3390/ijms241813942.
Research advances in current drugs targeting hyperlipidemia (Review).
Zhao H, Wang Y, Li Y, Cheng R, Chen W.
Mol Med Rep. 2025 Oct;32(4):258. doi: 10.3892/mmr.2025.13623. Epub 2025 Jul 19.
Hyperlipidemia and Cardiovascular Disease in People with Type 1 Diabetes: Review of Current Guidelines and Evidence.
Karmali R, Sipko J, Majid M, Bruemmer D.
Curr Cardiol Rep. 2023 May;25(5):435-442. doi: 10.1007/s11886-023-01866-x. Epub 2023 Apr 13.
Primary hyperlipidemia.
Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M; Committee for Epidemiology and Clinical Management of Atherosclerosis.
J Atheroscler Thromb. 2008 Apr;15(2):49-51. doi: 10.5551/jat.e590.
Effect modification of hyperlipidemia and hypertension on the association between type 2 diabetes and gout.
Tung YC, Lee MY, Wang YC, Chang CJ, Tsai WC, Lin GT, Li CY, Lee SS, Tu HP.
Prim Care Diabetes. 2020 Dec;14(6):654-662. doi: 10.1016/j.pcd.2020.06.002. Epub 2020 Jun 24.
Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
Duntas L, Kolovou G.
Future Cardiol. 2011 Mar;7(2):137-44. doi: 10.2217/fca.10.126.
Diagnosis of remnant hyperlipidaemia.
Paquette M, Bernard S, Baass A.
Curr Opin Lipidol. 2022 Aug 1;33(4):227-230. doi: 10.1097/MOL.0000000000000831.
Type I Hyperlipidemia.
Sloan RW.
Am Fam Physician. 1983 Nov;28(5):27.
